IP Library › Granted Patent US 12,281,317
Granted Patent B2
US 12,281,317 · App. 17/633,390 · Granted Apr 22, 2025

Non-human organism for producing triacylglycerol

Inventors: Peter Eastmond (Harpenden, GB); Henricus Egbertus Gerardus Van Erp (Harpenden, GB); Govindprasad Bhutada (Harpenden, GB)
Assignee: ROTHAMSTED RESEARCH LTD
C12N15/8247A23L33/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,317
App. No.
17/633,390
Granted
Apr 22, 2025
Kind
B2
Abstract

Described herein are non-human organisms for producing triacylglycerol wherein the non-human organism is genetically modified to express a lysophosphatidic acid acyltransferase specific for C16:0-Coenzyme A (C16:0 LPAT) and wherein, once expressed, the C16:0 LPAT is localised in the endoplasmic reticulum. Also described are non-human organisms for producing triacylglycerol in which (a) a lysophosphatidic acid acyltransferase specific for C16:0-Coenzyme A (C16:0 LPAT) is localised in the endoplasmic reticulum; and (b) activity of native endoplasmic reticulum lysophosphatidic acid acyltransferase (ER LPAT) is suppressed or prevented. Further described are non-human organisms in which a chloroplast lysophosphatidic acid acyltransferase (LPAT) is expressed, wherein said chloroplast LPAT lacks a functional chloroplast targeting signal. The disclosure also relates to methods for extracting triacylglycerol from the organisms and the use thereof in infant formula.

Claims (34)

1. A plant or fungal organism for producing triacylglycerol

(A) wherein the plant or fungal organism is genetically modified to express a lysophosphatidic acid acyltransferase specific for C16:0-Coenzyme A (C16:0 LPAT) and wherein, once expressed, the C16:0 LPAT is localised in the endoplasmic reticulum; or

(B) in which:

(a) a lysophosphatidic acid acyltransferase specific for C16:0-Coenzyme A (C16:0 LPAT) is localised in the endoplasmic reticulum; and

(b) activity of native endoplasmic reticulum lysophosphatidic acid acyltransferase (ER LPAT) is suppressed or prevented.

2. The plant or fungal organism according to claim 1 , wherein the activity of diacylglycerol conversion to and from phosphatidylcholine is suppressed or prevented.

3. The plant or fungal organism according to claim 1 , wherein the activity of phosphatidylcholine: diacylglycerol cholinephosphotransferase (PDCT) is suppressed or prevented.

4. The plant or fungal organism according to claim 1 , wherein the organism is an oilseed plant.

5. The plant or fungal organism according to claim 4 , wherein the plant is selected from Arabidopsis thaliana, Helianthus annuus, Glycine max, Camelina sativa and Brassica napus.

6. The plant or fungal organism according to claim 1 , wherein the organism is a yeast.

7. The plant or fungal organism according to claim 6 , wherein the organism is Yarrowia lipolytica.

8. The plant or fungal organism according to claim 1 , wherein the plant or fungal organism is cultured in a media comprising a carbon source, wherein the carbon source comprises (i) one or more sugars, and (ii) one or more fatty acids and/or fatty acid esters.

9. The plant or fungal organism m according to claim 8 , wherein the carbon source comprises a mixture of fatty acids and/or fatty acid esters wherein at least about 30% w/w of the fatty acids and/or fatty acid esters comprises C16:0 and/or at least about 30% w/w of the fatty acids and/or fatty acid esters comprises C18:1.

10. The plant or fungal organism according to claim 8 , wherein the media comprises glycerol.

11. The plant or fungal organism according to claim 1 , wherein the organism is cultured in a media comprising a carbon source, wherein the carbon source comprises palm oil.

12. The plant or fungal organism according to claim 11 , wherein the carbon source comprises palm oil in combination with glucose and/or glycerol.

13. The plant or fungal organism according to claim 1 , wherein the C16:0 LPAT is selected from:

(i) a chloroplast LPAT which lacks a functional chloroplast targeting sequence;

(ii) AGPAT1 (Human 1-acylglycerol-3-phosphate O-acyltransferase isoform 1);

(iii) CreLPAT;

(iv) Nannochloropsis sp. LPAT2;

(v) Nannochloropsis sp. LPAT3;

(vi) Nannochloropsis sp. LPAT4; and

(vii) Synechocystis sp. LPAT.

14. The plant or fungal organism according to claim 1 , wherein the plant or fungal organism expresses a FATB thioesterase.

15. The plant or fungal organism according to claim 1 , wherein the plant or fungal organism expresses a FATB thioesterase and is treated or genetically modified to disrupt the fatty acid desaturase 2 gene (FAD2).

16. The plant or fungal organism according to claim 1 , wherein the plant or fungal organism is treated or genetically modified to disrupt the KASII gene FAB1, fatty acid elongase gene (FAE1) and/or fatty acid desaturase 2 gene (FAD2).

17. The plant or fungal organism according to claim 1 , wherein (i) the plant or fungal organism expresses a FATB thioesterase and is treated or genetically modified to disrupt the fatty acid desaturase 2 gene (FAD2), (ii) conversion of diacylglycerol to phosphatidylcholine is suppressed or prevented in the plant or fungal organism, and (iii) activity of native endoplasmic reticulum lysophosphatidic acid acyltransferase (ER LPAT) is suppressed or prevented in the plant or fungal organism.

18. The plant or fungal organism according to claim 1 , wherein the plant or fungal organism is a plant.

19. A seed for producing a plant according to claim 18 .

20. A seed, fruit or a leaf obtained from a plant according to claim 18 .

21. A cell of the plant or fungal organism according to claim 1 .

22. A method for extracting triacylglycerol from the plant or fungal organism according to claim 1 .

23. A method for producing an infant formula, comprising obtaining triacylglycerol from a plant or fungal organism or a cell thereof according to claim 1 and using said triacylglycerol to produce an infant formula.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2022
From: EASTMOND, PETER; VAN ERP, HENRICUS EGBERTUS GERARDUS; BHUTADA, GOVINDPRASAD
To: ROTHAMSTED RESEARCH LTD
Reel/Frame 059157/0280 →
Priority Claims (1)
GB 1911317 · Aug 7, 2019 · national
Continuity (1)
Related Publication 20220282267A1 · Sep 8, 2022
References Cited (53)
US 5563058A · Davies · 1996 [cited by applicant]
US 5968791A · Davies et al. · 1999 [cited by applicant]
US 8524485B2 · Yadav · 2013 [cited by examiner]
US 9096834B2 · Seshadri · 2015 [cited by examiner]
US 10005713B2 · Petrie et al. · 2018 [cited by applicant]
US 20060094092A1 · Damude et al. · 2006 [cited by applicant]
US 20060206960A1 · Zou · 2006 [cited by applicant]
US 20110239323A1 · Hutcheon · 2011 [cited by applicant]
US 20180171312A1 · Davis · 2018 [cited by applicant]
AU 2013255080A1 · 2014 [cited by applicant]
AU 2020325789A1 · 2022 [cited by applicant]
CN 1331744A · 2002 [cited by applicant]
CN 102170774A · 2011 [cited by applicant]
CN 104364386A · 2015 [cited by applicant]
CN 105767213A · 2016 [cited by applicant]
CN 106016798A · 2016 [cited by applicant]
CN 106916798A · 2017 [cited by applicant]
CN 107960101A · 2018 [cited by applicant]
CN 114736916A · 2022 [cited by applicant]
CN 115786149A · 2023 [cited by applicant]
EP 2182071A1 · 2010 [cited by applicant]
EP 2966157A1 · 2016 [cited by applicant]
FR 2785911A1 · 2000 [cited by applicant]
KR 20220056928A · 2022 [cited by applicant]
WO 1998054303A1 · 1998 [cited by applicant]
WO 2003025165 · 2003 [cited by applicant]
WO 2009129582A1 · 2009 [cited by applicant]
WO 2013158938A1 · 2013 [cited by applicant]
WO 2013163684A1 · 2013 [cited by applicant]
WO 2014100467A1 · 2014 [cited by applicant]
WO 2016014968A1 · 2016 [cited by applicant]
WO 2016101894A1 · 2016 [cited by applicant]
WO 2016164495A1 · 2016 [cited by applicant]
WO 2021023991A1 · 2021 [cited by applicant]
Bhuiyan et al., “Determination and differentiation of triacylglycerol molecular species in Antarctic and non-Antarctic yeasts by atmospheric pressure-chemical ionization-mass spectrometry.” Journal of microbiological me… [cited by applicant]
Bourgis et al. “A plastidial lysophosphatidic acid acyltransferase from oilseed rape.” Plant physiology 120(3): 913-922 (1999). [cited by applicant]
Marudhupandi et al. “Heterotrophic cultivation of Nannochloropsis salina for enhancing biomass and lipid production.” Biotechnology Reports (10): 8-16 (2016). [cited by applicant]
Misra et al. “Genome-wide identification and evolutionary analysis of algal LPAT genes involved in TAG biosynthesis using bioinformatic approaches.” Molecular biology reports 41(12): 8319-8332 (2014). [cited by applicant]
Nobusawa et al. “Differently localized lysophosphatidic acid acyltransferases crucial for triacylglycerol biosynthesis in the oleaginous alga Nannochloropsis.” The Plant Journal 90(3): 547-559 (2017). [cited by applicant]
Simpson et al. “A novel pathway for triacylglycerol biosynthesis is responsible for the accumulation of massive quantities of glycerolipids in the surface wax of bayberry ( [cited by applicant]
Van Erp et al. “Engineering the stereoisomeric structure of seed oil to mimic human milk fat.” Proceedings of the National Academy of Sciences 116(42): 20947-20952 (2019). [cited by applicant]
Wang et al. “Establishment of an evaluation model for human milk fat substitutes.” Journal of agricultural and food chemistry 58(1): 642-649 (2010). [cited by applicant]
Wang et al. “Dual expression of plastidial GPAT1 and LPAT1 regulates triacylglycerol production and the fatty acid profile in Phaeodactylum tricornutum.” Biotechnology for biofuels 11(1): 1-14 (2018). [cited by applicant]
Wei et al. “Human milk fat substitutes: Past achievements and current trends.” Progress in lipid research (74): 69-86 (2019). [cited by applicant]
Bhutada et al. “Production of human milk fat substitute by engineered strains of Yarrowia lipolytica” Metabolic Engineering Communications 14:e00192 (Jan. 6, 2022). [cited by applicant]
“Study on important nodes related to triglyceride synthesis and accumulation pathway in Phaeodactylum tricornutum” (2018). [cited by applicant]
Van Erp et al. “Production of the infant formula ingredient 1,3-olein-2-palmitin in [cited by applicant]
Kim et al. “Plastid lysophosphatidyl acyltransferase is essential for embryo development in [cited by applicant]
Kim et al. “Endoplasmic reticulum acyltransferase with prokaryotic substrate preference contributes to triacylglycerol assembly in Chlamydomonas.” Proceedings of the National Academy of Sciences 115.7: 1652-1657 (2018). [cited by applicant]
Robertson et al. “A two-helix motif positions the lysophosphatidic acid acyltransferase active site for catalysis within the membrane bilayer.” Nature structural & molecular biology 24.8: 666-671 (2017). [cited by applicant]
Weier et al. “Characterisation of acyltransferases from [cited by applicant]
Yamaoka et al. “Identification of a Chlamydomonas plastidial 2-lysophosphatidic acid acyltransferase and its use to engineer microalgae with increased oil content.” Plant biotechnology journal 14.11: 2158-2167 (2016). [cited by applicant]
Zhang et al. “Cloning, characterization, and expression analysis of a gene encoding a putative lysophosphatidic acid acyltransferase from seeds of Paeonia rockii.” Applied Biochemistry and Biotechnology 182: 721-741 (20… [cited by applicant]